Acadia Pharmaceuticals reported $178.32M in Trade Debtors for its fiscal quarter ending in September of 2026.





Trade Debtors Change Date
Acadia Pharmaceuticals USD 178.32M 11.98M Sep/2026
ALKERMES USD 459.09M 2.61M Sep/2026
Alnylam Pharmaceuticals USD 1.08B 172.17M Sep/2026
Biogen USD 2.38B 15.8M Sep/2026
BioMarin Pharmaceutical USD 1.08B 15.31M Sep/2026
Bristol-Myers Squibb USD 12.85B 976M Sep/2026
Cara Therapeutics USD 2.24M 2.26M Mar/2025
Corcept Therapeutics USD 111.06M 34.14M Sep/2026
Cytokinetics USD 24.43M 17.6M Jun/2026
Eisai JPY 237.44B 15.69B Sep/2026
Eli Lilly USD 23.48B 2.3B Jun/2026
Incyte USD 1.24B 111.82M Sep/2026
J&J USD 19.05B 3.49B Jun/2026
Moderna USD 1.37B 1.35B Sep/2026
Neurocrine Biosciences USD 957.3M 70.3M Sep/2026
Pfizer USD 17.57B 1.38B Sep/2026
Prothena USD 5.16M 0 Dec/2023
PTC Therapeutics USD 239.04M 19.12M Jun/2026
Sarepta Therapeutics USD 385.98M 7.82M Sep/2026
Ultragenyx Pharmaceutical USD 200M 140M Jun/2026
Vanda Pharmaceuticals USD 47.1M 4.35M Dec/2024
Vertex Pharmaceuticals USD 2.31B 176.7M Sep/2026